DC Funds’s Werewolf Therapeutics HOWL Stock Holding History

DC Funds’s Portfolio HOWL Stock Details HOWL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$212K	Hold	589,102	–	–	16.92%	3
2026 Q1	$490K	Hold	589,102	–	–	33.01%	2
2025 Q4	$373K	Hold	589,102	–	–	25.69%	3
2025 Q3	$1.16M	Hold	589,102	–	–	37.32%	1
2025 Q2	$642K	Hold	589,102	–	–	29.83%	2
2025 Q1	$573K	Hold	589,102	–	–	27.71%	3
2024 Q4	$872K	Hold	589,102	–	–	24.47%	2
2024 Q3	$1.25M	Hold	589,102	–	–	24.25%	2
2024 Q2	$1.44M	Hold	589,102	–	–	23.87%	2
2024 Q1	$3.82M	Hold	589,102	–	–	36.89%	2
2023 Q4	$2.27M	Hold	589,102	–	–	27.34%	3
2023 Q3	$1.26M	Hold	589,102	–	–	25.95%	3
2023 Q2	$1.8M	Hold	589,102	–	–	38.27%	1
2023 Q1	$1.53M	Hold	589,102	–	–	35.68%	1
2022 Q4	$1.21M	Hold	589,102	–	–	32.7%	2
2022 Q3	$2.66M	Hold	589,102	–	–	40.05%	1
2022 Q2	$2.41M	Hold	589,102	–	–	33.24%	2
2022 Q1	$2.59M	Buy	589,102 +8,200	+1%	+$57.4K	33.68%	2
2021 Q4	$6.92M	Sell	580,902 -8,200	-1%	-$124K	40.97%	2
2021 Q3	$10.1M	Hold	589,102	–	–	39.69%	1
2021 Q2	$10.3M	Buy	+589,102	New	+$8.07M	48.81%	2

Other funds holding HOWL

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Verdad Advisers Boston, Massachusetts $104M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

DC Funds's HOWL Position: Q2 2026 in Review

DC Funds held its Werewolf Therapeutics (HOWL) position steady in Q2 2026 at 589,102 shares worth $212K. The position accounts for 16.92% of the portfolio, ranked #3.

DC Funds first reported a position in HOWL in Q2 2021 and has held it in 21 quarters since. The position peaked at $10.3M in Q2 2021. 45 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

DC Funds held 589,102 shares of Werewolf Therapeutics worth $212K as of Q2 2026.
DC Funds left its Werewolf Therapeutics share count unchanged in Q2 2026.
Werewolf Therapeutics made up 16.92% of DC Funds's portfolio in Q2 2026, its #3 holding.
DC Funds first reported a position in Werewolf Therapeutics in Q2 2021 and has held it in 21 quarters since.
DC Funds's Werewolf Therapeutics position peaked at $10.3M in Q2 2021.
45 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on DC Funds's 13F filing for Q2 2026, filed 14 Aug 2026.